Physician profile
Faizullah Syed
NPI 1902845589
$3,358.97
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,962 · 2020: $1,396.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $2,572.95 | 2019-2020 | |
| Novo Nordisk INC | $134.48 | 2019 | |
| Indivior INC. | $97.16 | 2019 | |
| Allergan, INC. | $63.47 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $50.04 | 2019 | |
| Glaxosmithkline, LLC. | $44.74 | 2019-2020 | |
| Astellas Pharma US INC | $35.41 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $33.63 | 2019 | |
| Amarin Pharma, INC. | $27.96 | 2020 | |
| Lilly USA, LLC | $25.00 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $21.87 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.69 | 2019 | |
| Vifor Pharma, INC. | $13.81 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.30 | 2019 | |
| Daiichi Sankyo INC. | $13.25 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $13.01 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $11.64 | 2020 | |
| Amgen INC. | $11.62 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.23 | 2019 | |
| Pfizer INC. | $11.14 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Research and ownership
$3,616.98 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faizullah Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.